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Over the last few decades of biomedical research, animal models of neuromuscular diseases have
been widely used for determining pathological mechanisms and for testing new therapeutic
strategies. With the emergence of high-throughput proteomics technology, the identification of
novel protein factors involved in disease processes has been decisively improved. This review
outlines the usefulness of the proteomic profiling of animal disease models for the discovery of
new reliable biomarkers, for the optimization of diagnostic procedures and the development of
new treatment options for skeletal muscle disorders. Since inbred animal strains show geneti-
cally much less interindividual differences as compared to human patients, considerably lower
experimental repeats are capable of producing meaningful proteomic data. Thus, animal model
proteomics can be conveniently employed for both studying basic mechanisms of molecular
pathogenesis and the effects of drugs, genetic modifications or cell-based therapies on disease
progression. Based on the results from comparative animal proteomics, a more informed deci-
sion on the design of clinical proteomics studies could be reached. Since no one animal model
represents a perfect pathobiochemical replica of all of the symptoms seen in complex human
disorders, the proteomic screening of novel animal models can also be employed for swift and
enhanced protein biochemical phenotyping.
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1 Introduction
A major focus of modern biological research is to elucidate
the molecular and cellular mechanisms that underlie human
health and disease. Over the last few decades, both naturally
occurring and genetically engineered animal models of hu-
man diseases have been employed for evaluating new ther-
apeutic options and for elucidating pathological pathways [1–
9]. In conjunction with findings from clinical investigations,
biological studies of animal models can be extremely helpful
for the initial evaluation of alternative treatment strategies
[10–12]. Genetic manipulations via transgenic or gene
knockout technology can provide crucial information prior to
the development of drug or gene therapy approaches to
counter-act symptoms in human disorders [13, 14]. In addi-
tion, the potential outcome of cell-based therapies involving
different kinds of stem cells can be mimicked through ani-
mal model research [15–17]. Currently, a variety of animal
species are used for the detailed biochemical, cell biological
and physiological analysis of almost all major human dis-
eases [1–9], and are applied in essential toxicological investi-
gations to determine the potential side effects of new phar-
macological agents or treatment regimes [18, 19].
The traditional reductionist approach to investigating the
pathobiochemical problems by focusing on single proteins,
protein complexes or isolated pathways, has inevitably been
criticized due to its limited scope in understanding bio-
medical phenomena at the systems level [20]. Although the
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last decades of biomedical research have produced a
remarkable series of scientific breakthroughs on the eluci-
dation of diseasemechanisms, this vast biological knowledge
had surprisingly little effect on the improvement of drug
targeting. Although it is estimated that several hundred
thousand different protein species or isoforms exist in the
various human cell types, which represent a gigantic cohort
of potential pharmacological targets, only a few hundred tar-
get-families are actually recognized by traditional drug dis-
covery approaches [21]. Thus, detailed knowledge of a pri-
mary genetic abnormality or cellular mechanisms that
underlie pathological processes does not necessarily trans-
late into rationale drug design or improved cell-based thera-
pies. Modern systems biology based on the graph and sys-
tems theory may succeed through mathematical modelling
to deliver a better understanding of complex biological and
pathological processes, but will heavily depend on reliable
sets of data for producing relevant biomedical predictions
[22]. In this respect, high-throughput genomic, proteomic
and metabolomic technology will be an absolutely essential
component in delivering these kinds of analytical results.
The tremendous technical advances in the high-
throughput screening of peptides by MS have established a
new analytical capability in the biological sciences [23]. It is
now possible to identify large portions of the protein com-
plement of a given cellular system in one swift analytical
approach [24–26]. Naturally, the application of proteomics
has also revolutionized the study of animal models mimick-
ing human diseases. A better understanding of animal
models of disease through genomics, proteomics and meta-
bolomics is already clearly evident in the field of biomedicine
[27–29]. Since the screening of patient samples usually
requires very large experimental repeats due to considerable
interindividual differences in humans, the usage of inbred
and therefore genetically more homogeneous animal models
is certainly advantageous in the initial search for new bio-
markers of pathological processes. This allows animal model
research in general and the proteomic profiling of species,
that represent important aspects of human pathology, in
particular a central place in modern biomedicine. Based on
the findings from animal model proteomics, a more
informed decision on the design of clinical proteomics stud-
ies could be achieved.
This review outlines the importance of studying animal
disease models for enhancing our understanding of the fun-
damental pathological principles, critically examines the
limitations of extrapolating animal data to the human sub-
ject and discusses how the identification of novel disease
markers from animal studies can be used as a starting point
for more in-depth medical investigations. It is clear from our
current state of biomedical knowledge that it will be essential
to develop better animal models that more closely resemble
the various aspects of human pathology and to characterize
already established animal strains in more detail. A more
thorough biochemical analysis of animal models by com-
parative proteomics has an enormous potential to accelerate
the process of improving diagnostic procedures and to deci-
sively refine the development of new therapeutic strategies
for the preventative and ameliorative treatment of all major
classes of human disorders.
2 Biomedical importance and
pathobiochemical limitations of animal
disease models
Despite the ongoing ethical debate about whether it is justi-
fiable to generate new, or manipulate established animal
models, on purpose for biomedical research [30], it is clear
that the biological analysis of animal models that mimic hu-
man diseases has led to a better understanding of numerous
pathological mechanisms and was extremely helpful in the
initial testing of new therapeutic strategies [1–9]. If the bio-
logical fact, that animal models usually do not represent a
perfect replica of all pathobiochemical aspects seen in a
highly complex human pathology, is properly taken into
account, studying genetically engineered or naturally occur-
ring species can yield important results of clinical relevance
[13, 14]. However, it is important to keep the limitations of
animal experiments in mind and that the extrapolation of
animal data to the human situation is sometimes very diffi-
cult due to species-specific differences. Small rodents com-
monly used in biological research may exhibit fundamental
physiological differences as compared to humans. This
includes differences in development, cellular differentiation,
potential for tissue regeneration, mechanisms of cell regen-
eration, immune responses, susceptibility to infection, pat-
terns of detoxification of xenobiotics, metabolism and bio-
energetics. Variations in basic biological mechanisms such
as the maintenance of ion homeostasis, cell signalling, hor-
monal regulation or metabolic integration may exist between
cellular systems in animal models versus human patients.
Furthermore, differences in compensatory mechanisms or
redundant pathways between different species may compli-
cate the interpretation of results from animal experiments. It
is therefore essential to properly evaluate a new animal
model prior to employing such a biological system in elabo-
rate large-scale studies for testing new drugs or biomedical
treatments. The biological integration of genomic, proteomic
and physiological data sets from both human and animal
model analyses will be an important aspect towards unravel-
ling the fundamental differences between species [31, 32].
Taking into account the above outlined potential prob-
lems with biomedical data generated from animal experi-
ments, a good animal model should exhibit the following
characteristics. Ideally, it should (i) closely resemble the
etiology of the human disease in onset, progression, com-
plexity and severity, (ii) develop all or most of the multi-
factorial aspects usually observed in end-stage human
pathology, (iii) mimic the basic mechanisms of human
physiology and metabolism that are important for disease
progression or drug treatment, (iv) exhibit similar primary
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genetic abnormalities in the case of inherited disorders,
(v) show comparable susceptibility to infectious or pharma-
cological agents in the case of infectious or pharmacogenetic
diseases, (vi) be suitable for genetic manipulations and cell-
based treatment strategies and (vii) be large enough to yield
sufficient amounts of biological samples for extended bio-
chemical analyses or to facilitate physiological and surgical
procedures [1, 2, 10]. The ease of breeding, housing and
sampling are obviously other important criteria for choosing
a suitable animal model. With respect to the humane and
responsible use of animal models in biomedical research, an
important bioethical objection is often associated with the
usage of larger animals. This makes smaller rodents, espe-
cially genetic mouse models, the most frequently used spe-
cies [3, 4, 14]. It is important to stress that different animal
strains might be necessary for properly studying the various
aspects of a multifactorial human disease.
3 Animal model proteomics
Although the usage of human cell cultures can give highly
relevant data with respect to therapeutic dosage and toxic
side effects [33], whole-animal studies will probably still form
a central part of pharmacological and biomedical evaluations
in the foreseeable future [34, 35]. Cells in culture or co-cul-
ture often lack important aspects of differentiation and
usually do not exhibit heterogeneous cell–cell interactions to
the same degree as seen in tissues. In pharmacological
studies, cell culture models cannot be employed to mimic
the complexity of adsorption, distribution, first-pass hepatic
elimination, modification and excretion of a drug. Besides
the liver, biotransformation may involve many other tissues
and can trigger severe organ-selective toxicity that can only
be studied at the whole-body level [36, 37]. In the past, hy-
pothesis-driven studies on animal models have focused on
specific proteins, families of protein factors or pathways,
greatly limiting the meaningfulness of experimental results
with respect to understanding biological processes at the
systems level. With the emergence of high-throughput pro-
teomics technology, the biochemical characterization of ani-
mal models has been decisively improved. Technology-
driven approaches in modern protein biochemistry has led to
the development of analytical flow schemes for the fast and
efficient identification of novel protein factors involved in
disease processes.
Following the development of genetically engineered
animal models or the discovery of naturally occurring dis-
ease models, the basic determination of genetic, physiologi-
cal, histological and anatomical characteristics has to be car-
ried out in order to judge the phenotype of a new experi-
mental species. To properly mimic human symptoms, the
onset, severity and progression of the disease should be
similar in the animal model. In addition, basic physiological,
metabolic and anatomical aspects also have to be taken into
account when one judges the usefulness of an animal model.
Once a suitable biological system has been established, MS-
based proteomic screening can be used to identify new can-
didate proteins with a changed expression level. While
genomic data can only predict the effects of changes in gene
expression on the actual concentration of proteins or the
extent of PTMs, proteomics can accurately provide the status
of protein abundance, isoform expression patterns and pep-
tide modification. The large-scale proteomic profiling of
proteins has enhanced the analytical capabilities to such an
extent that it is now possible to study thousands of individual
protein species in parallel [38–40]. As an illustrative example,
see below the DIGE analysis of the dystrophic diaphragm
from the mdx model of Duchenne muscular dystrophy
(DMD) [41]. Soluble proteins can be conveniently studied by
2-DE [25, 42], while more insoluble membrane proteins are
mostly analysed via LC [43]. MS-based proteomics is also
highly suitable for determining important PTMs [44], which
has established the high-throughput determination of dis-
ease-related changes in the phosphoproteome or the glyco-
proteome as a routine biochemical investigation.
Thus, in the modern biochemical laboratory, proteomic
profiling represents the most powerful tool for the swift
separation and identification of new biomarkers that exhibit
altered expression levels in pathological tissues. Initial pro-
teomics data should be confirmed by peptide sequencing,
immunoblotting and/or immunofluorescencemicroscopy in
order to establish a new cohort of potential disease marker
proteins. For comparative searches, the existence of interna-
tional data banks with standardized 2-D gel patterns of all
major organ and tissue systems from established animal
models can greatly simplify the identification of a new dis-
ease marker [45, 46]. Once interesting candidate proteins
have been found by animal model proteomics, an informed
decision can be made on the optimum design of subsequent
clinical studies. For example, instead of screening total
extracts from human tissue specimens or separating the
entire accessible protein complement, pathobiochemical
studies can focus on particular subcellular fractions or only
isolate subfractions with a specific biochemical property. If
differential centrifugation steps, affinity isolation techniques
or density gradient centrifugation methods do not lead to
artefacts of enrichment or detachment of biomolecules, the
analysis of low-abundance or relatively insoluble marker
proteins should be best executed with subcellular fractions.
Groups of soluble human proteins that exhibit a restrict-
ed range of pI-values and/or molecular masses, can be sepa-
rated at a higher resolution by optimizing the IEF gradient
and polyacrylamide concentration during 2-DE. If a new
candidate protein has been shown to exist in large oligomeric
clusters in healthy tissue, it might be worthwhile to evaluate
its supramolecular status by intraproteomics. The fast isola-
tion of large numbers of homogeneous protein species by
preparative IEF or continuous gel electrophoresis, followed
by conjugation to a signalling enzyme such as peroxidase,
has the potential for being useful for high-throughput intra-
proteomics [47]. If a protein has been shown to be abnor-
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mally oligomerized or being of significant lower or higher
concentration in an animal model, a simple comparative
immunoblot analysis of age-and gender-matched normal
versus pathological human biopsy material can quickly and
efficiently give new insights into a disease process. Thus the
initial discovery of new biomarkers by animal model prote-
omics, in conjunction with subsequent detailed clinical
studies, has the potential for improving diagnostic proce-
dures in the short-term and is helpful in the establishment of
novel therapeutic targets in the long-term.
Since most animal models do not reflect all of the com-
plex symptoms of a multifactorial human disease or do not
properly mimic the severity or progression of the disorder
[10], the usage of multiple strains of genetically engineered
or natural species is often necessary [48]. In addition, in
genetic diseases different tissues or organs may be affected
to a varying degree in animal models versus patients. This
makes the development of new disease models that exhibit
specific aspects of a human disorder very important. An
essential parameter during the production of new biomedi-
cal systems is the effective phenotyping of a new animal
strain, so that a quick decision can be made on its pathologi-
cal reliability. For example, the phenotyping of new genetic
mouse models of diabetes has to take into account all aspects
of diabetic complications, including the effects of obesity and
related cardiovascular and kidney disorders, and be carried
out by standardized high-quality metabolic and physiological
tests [49]. In order to fully evaluate a metabolic syndrome in a
genetically engineered mouse, testing would include meas-
urements of general carbohydrate levels, whole-body glucose
metabolism, lipids and cholesterol, as well as body composi-
tion, eating behaviour and activity. Important aspects are also
food and fat absorption, and the response of the animal to
interventions such as fasting, exercise or a high-fat diet.
More specialized metabolic investigations would study the
mechanisms of aberrant insulin signalling during hormonal
resistance using isotopic measurements of intracellular
metabolic pathway fluxes in peripheral organs, such as liver
and muscle. In addition, metabolic changes on the level of
the regulation of glycolysis versus gluconeogenesis, citric acid
cycle fluxes, sources of plasma glucose, nutrient oxidation
and futile metabolic cycle fluxes also have to be taken into
account if one wants to fully understand the phenotype of a
new animal model of diabetes [50–52].
4 Proteomics of muscle degeneration
Skeletal muscle represents the most abundant tissue in the
human body and is involved in many essential physiological
and biochemical processes, including movement, posture,
heat homeostasis and metabolic integration [53]. Mechanical
loading and neuromuscular activity play an important role in
the maintenance of muscle fibre integrity. This is clearly il-
lustrated by the effects of external electro-stimulation or fibre
denervation on muscle mass and strength [54–56]. Termina-
tion or changes at the essential nerve–muscle connection
lead to drastic alterations in gene expression and conse-
quently alterations in protein abundance and isoform pat-
terns. Chronic low-frequency stimulation of a fast muscle
induces a stepwise transition of the contractile apparatus,
energy metabolism, ion homeostasis and regulation of the
excitation–contraction–relaxation cycle [57]. Thus, the study
of skeletal muscle pathology always has to take into account
the important influence of the innervating motor neuron on
the differentiation of the fibre population that constitutes a
motor unit. The degeneration of skeletal muscles or abnor-
mal muscle metabolism plays an important role in many
human diseases, including both disorders with primary
muscle pathology or those that indirectly affect the muscu-
lature via neuronal or metabolic abnormalities. Muscle dis-
eases encompass inherited disorders such as X-linked mus-
cular dystrophies of the type Duchenne or Becker, limb-
girdle muscular dystrophies and congenital muscular
dystrophy, acquired autoimmune disorders such as myas-
thenia gravis, and pharmacogenetic diseases such as malig-
nant hyperthermia [53]. A typical neuromusclar disorder is
motor neuron disease, which exerts a drastic secondary
pathology on affected muscle fibres [53]. Extreme forms of
the age-related decline in muscle function can also be con-
sidered a pathological process, whereby sarcopenia of old age
is an excellent example of a highly complex multifactorial
human disease. Recently, several studies on the proteomic
profiling of animal models mimicking muscular dystrophy
[41, 58–61] and sarcopenia [62–65] have been published.
Since muscle fibres can be subdivided into different types of
predominantly fast- or slow-twitching cells and because dif-
ferentiated skeletal muscles remain highly plastic in their
adaptive capabilities, the proteomics of fibre typing [66–69]
andmuscle transformation [70] has also been of considerable
interest to cell biologists. Below we outline the results of
these studies and describe the beginnings of skeletal muscle
proteomics as a new biochemical field in basic and applied
myology.
4.1 Proteomic profiling of muscle fibre types
To standardize the proteomic analysis of animal models with
respect to a heterogeneous and highly plastic class of tissue
such as skeletal muscles, it is important to establish the
comprehensive 2-D reference maps of the proteome from
the most frequently used experimental species. Reproducible
2-D spot patterns and the MS-based identification of the
most abundant soluble muscle proteins has been carried out
for two important biomedical species, the mouse [46] and the
rat [71], whereby the overall distribution pattern of key mus-
cle proteins is relatively comparable to the human fibre pro-
teome [72, 73]. The proteomic profiling of fast versus slow
muscles is crucial for the identification of reliable bio-
markers that can differentiate between fibre type-specific
disease processes. The transition of fibre types occurs during
normal physiological adaptations to changed functional
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demands, such as extensive physical training or exposure to
zero-gravity environments [74, 75], and in certain neuro-
muscular diseases or clinical treatments such as dynamic
cardiomyoplasty [76]. The proteomic cataloguing of fibre
type-specific muscle markers has been carried out for four
animal species of importance for biomedical research, i.e. the
mouse [67], the rat [69], the rabbit [70] and the pig [66]. These
studies have confirmed the results from previous physiolog-
ical and biochemical studies and have clearly established the
various isoforms of the myosin heavy chain, myosin light
chain, actin, troponins and tropomyosins as reliable indica-
tors of fibre type distribution [66–70]. In addition, the prote-
omic analysis of animal muscles has lead to a better under-
standing of protein dynamics under conditions of rapid
growth [77], neuromuscular junction formation [78] and
exercise-induced changes in the muscle proteome [79] and
mitochondrial differences between the heart and skeletal
muscle [80].
Over the last few decades of skeletal muscle research, the
view that muscles represent a homogeneous tissue with
restrictive adaptable potential has dramatically changed [54].
It is now clear that skeletal muscles are highly versatile and
can undergo a rapid transformation process involving trans-
differentiation between different fibre types, the recruitment
of the myo-selective stem cell pool of satellite cells and their
subsequent innervation-dependent differentiation, and a
certain degree of cellular destruction and regeneration cycles
[56]. The chronic low-frequency stimulation of predomi-
nantly fast-twitching muscles, such as the rabbit tibialis
anterior, can be used to investigate the stepwise responses of
fast muscles to enhance neuromuscular activity under con-
ditions of maximum activation [57]. Chronic conditioning
triggers profound physiological, biochemical and histologi-
cal changes including a slower twitch pattern of the con-
tractile apparatus, an elevated aerobic-oxidative capacity, a
drastically higher resistance to fatigue, smaller calibre cells,
an increase in the half-relaxation time and the time-to-peak
twitch tension, as well as the changes in the density and iso-
form expression pattern of proteins involved in the regula-
tion of excitation–contraction (EC) coupling, ion home-
ostasis, the contractile machinery, metabolic integration and
signal transduction [56, 57]. The biochemical alterations
during the fast-to-slow transition process were confirmed by
the MS-based proteomic analysis of chronic low-frequency
stimulated rabbit fast muscles [70]. The observed changes in
16 identified biomarkers of muscle transformation have
demonstrated that, besides myosin isoform switching, also
an increased availability of oxygen for aerobicmetabolism via
myoglobin transport, the optimum utilization of free fatty
acids via increased albumin transportation, a rearrangement
of the creatine kinase isozyme pattern for enhanced mito-
chondrial activity, and the up-regulation of stress proteins for
stabilising myofibrillar components with chaperones is cru-
cial for muscle plasticity. Changes in glycolytic enzymes of
the cytosol versus citric acid cycle components and other
mitochondrial elements have been found to be suitable for
determining fibre type shifting [70]. The transition of easily
fatiguing muscle fibres into fatigue-resistant aerobic fibres
appears to be an extremely complex biological process.
Building on these encouraging findings, hopefully the
application of the more discriminatory DIGE method will
lead to the identification of a larger and better cohort of fibre
type-specific marker proteins in the future.
4.2 Animal models of muscle degeneration
Although adult muscle wasting diseases are not as frequent
as heart failure, liver disease or cancer, neuromuscular dis-
orders play an important role in the field of inherited child-
hood diseases and in gerontology [53]. Since this review is
concerned with animal model proteomics and because
recent proteomic profiling studies have been carried out with
dystrophic and aged muscles, we have focused our discus-
sion on X-linked muscular dystrophy and sarcopenia of old
age. Muscular dystrophies are a clinically well-characterized
group of inherited muscle wasting disorders that can be
subdivided based on their primary genetic abnormalities into
X-linked Duchenne/Becker muscular dystrophy, Emery-
Dreifuss muscular dystrophy, limb-girdle muscular dystro-
phy, congenital muscular dystrophy, distal muscular dystro-
phy, Bethlem myopathy and myotonic dystrophy [81, 82].
Figure 1A shows the severe pathology of Duchenne mus-
cular dystrophy. A transverse cryosection, stained with hae-
matoxylin and eosin, exhibits fibres of abnormal rounded
contour and with varying diameter. The histologically most
striking feature is the infiltration of connective and fatty tis-
sue, causing severe muscle weakness in Duchenne patients.
A great variety of animal models exist for these muscular
dystrophies including the X-linked dystrophic mdx mouse
and its related mutants generated by genetic engineering or
chemical mutagenesis, the Duchenne-like dystrophic dog
model grmd, the dy mouse model of congenital muscular
dystrophy, the various Sgc mice mimicking limb-girdle
muscular dystrophies, and the Miyoshi myopathy-like SJL
mouse with a deficiency in dysferlin. See the recent reviews
for a comprehensive listing of animal models of muscular
dystrophy [7, 16, 83–86].
The mdx mouse is a naturally occurring animal model of
dystrophinopathy and exhibits many of the symptoms of
muscle degeneration seen in human X-linked muscular
dystrophy [87]. While mdx limb muscles exhibit relatively
mild dystrophic changes [88], the diaphragm muscle is
severely necrotic [89]. Skeletal muscles fibres from the mdx
mouse have a point mutation in the dystrophin gene causing
the near-to-total absence of the Dp427 isoform of this mem-
brane cytoskeletal protein [90] and a concomitant reduction
in dystrophin-associated glycoproteins such as dystroglycans
(DGs), sarcoglycans (SG), syntrophins (SYN), sarcospan (SS)
and dystrobrevins (DBs) [91]. In analogy to human dys-
trophic muscles, mdx fibres are characterized by varying
degrees of necrosis, the appearance of regenerated myofibres
with central nucleation, an increased susceptibility to os-
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Figure 1. Histopathological comparison between DMD and the
mdx mouse model of X-linked muscular dystrophy. Shown are
10 mm-thick transverse cryosections from human (A, C) and
mouse (E) dystrophic skeletal muscle fibres and, for comparison,
normal human (B) andmouse (D) muscles, respectively. Sections
were stained with haematoxylin and eosin [91]. The specimens
from the DMD patients exhibit signs of varying fibre size and
infiltration of connective tissue. The mdx sample shows a high
degree of central nucleation indicating repeated cycles of
degeneration and regeneration. Bar = 100 mm.
motic shock, elevated levels of serum creatine kinase,
stretch-induced injury, abnormal Ca21-handling and
impaired (EC) coupling [91–96]. Figure 1 shows the histo-
pathological analysis of dystrophin-deficient fibres. The hae-
matoxylin and eosin stained transverse sections show the
dystrophic phenotype in a biopsy from a Duchenne patient
versus the mdxmousemodel of dystrophinopathy. In contrast
to normal human and mouse skeletal muscle fibres (Figs. 1B
and D), which show a regular distribution pattern and very
little surrounding connective tissue, fibres from Duchenne
muscle show severe dystrophic changes (Fig. 1C) and mdx
fibres mildly dystrophic alterations with variations in cell di-
ameter and extensive central nucleation (Fig. 1E). Interest-
ingly, distal muscle groups in the eye and toe represent pro-
tected phenotypes in the mdx mouse [97–99], which is pos-
sibly due to the up-regulation of the autosomal dystrophin-
homologue named utrophin. The utrophin isoformUp395 is
usually enriched at the neuromuscular junction [100], but
found at high concentrations in extrajunctional sarcolemmal
region in certain distal mdxmuscles [97, 98]. Besides an utro-
phin-related rescue of the dystrophin-associated glycoprotein
complex in extraocular muscles, possibly the small diameter
and fast-twitch properties might result in a decreased load-
bearing of these protected dystrophin-deficient fibres.
It is of considerable biomedical importance to elucidate
the basic biochemical differences between severely necrotic
diaphragm muscles, mildly dystrophic limb muscles and
protected extraocular muscles from mdx mice. A differential
effect of primary abnormalities on different subtypes of skel-
etal muscle is also present in human patients. It is not well
understood why certain skeletal muscle groups are targeted
or spared in a variety of neuromuscular diseases [81, 99].
Basic differences in molecular composition, physiological
regulation, cellular structure and/or contractile properties
may render fibres more or less susceptible to degenerative
processes. In the case of the mdx mouse model of X-linked
muscular dystrophy, the three main types of skeletal muscle
are differentially affected [101]. Since the different fibre sub-
types are present in the same animal model with the same
primary genetic abnormality, compensatory mechanisms or
physiological differences have to account for the variations in
pathological features. Perhaps future comparative proteom-
ics analyses of the three different mdx muscle types will shed
light on these mechanisms and thereby identify new bio-
markers involved in the natural rescue of the dystrophic
phenotype [99]. The idea that full-length dystrophin and
utrophin are functionally interchangeable isoforms and that
increased utrophin levels are responsible for the milder mdx
phenotype as compared to Duchenne patients, is supported
by the analysis of the mdx/utrn2/2 mouse model [101–104].
This animal model of severe muscular dystrophy is deficient
in both dystrophin and utrophin and exhibits weight loss,
growth retardation, spinal curvature, joint contractures and
premature death [101]. A comparative cataloguing of the
muscle proteome of the mdx versus the mdx/utrn2/2 mouse
model of muscular dystrophy might be a useful starting
point to explore the different patterns of fibre degeneration
in the presence and absence of the Up395 isoform.
In addition to mammalian disease models, zebrafish and
the nematode Caenorhabditis elegans have recently been used
as nonmammalian models of muscle degeneration [86]. Both
species express a dystrophin homologue and can be
employed in large-scale genetic studies due to the ease of
maintaining them in large numbers. Furthermore, their
musculature and physiological control mechanisms are less
complicated as compared to mammalian species, which
makes them ideal high-throughput test systems for gene
manipulation and pharmacological pilot studies [86]. The
successful application of dystrophic models over the last few
years has revealed the usefulness of animal models in
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applied biomedical research. New therapeutic strategies such
as gene transfer methods (including viral infection, nonviral
infection or antisense oligonucleotide approaches) or cell-
based strategies (such as stem cell therapy or myoblast
transfer) have all been tested in animal models of muscular
dystrophy, mostly the mdx mouse [85]. Interestingly, the
delivery of utrophin to neonatal mdx/utrn2/2 mice reduced
the degree of necrosis in this animal model of severe mus-
cular dystrophy [104], indicating that utrophin-based re-
placement therapies might be an option to treat progressive
fibre degeneration in dystrophinopathies [105].
For the analysis of age-related muscle degeneration, var-
ious rat skeletal muscles are frequently used in biochemical
studies. Muscle biopsy samples isolated from humans ex-
hibit a high degree of interindividual differences, as recently
shown in the analysis of vastus lateralis biopsies from male
humans aged 18–82 years [106], making animal models of
sarcopenia the preferred test system for initial proteomic
studies. Established animal models of aging are represented
by WI/HicksCar rats [107] and Fisher 344 rats [62]. The
pathological profile of aged animals is often associated with
other common aging-related diseases, such as diabetes, heart
failure and cancer. It is, therefore, important to differentiate
between unrelated aspects of pathophysiological mechan-
isms in the senescent organism. WI/HicksCar skeletal mus-
cles exhibit age-related EC uncoupling and can be used as a
suitable animal model of sarcopenia [107]. Depending on the
particular rat strain, their average life span is between 24 and
34 months [62]. The majority of researchers in the field con-
sider 4 months of age young, 12 months of age adult,
24 months of age old and 36 months of age senescent [64,
108, 109]. Below is a description of the proteomic profiling of
skeletal muscles in animal models mimicking X-linked
muscular dystrophy and sarcopenia of old age.
4.3 Proteomic profiling of dystrophic mdx muscles
Besides the proteomic analysis of immobilization-induced
muscular atrophy in the rat [110, 111], fibre type changes in
kyphoscoliotic mouse muscle [67], and age-dependent mus-
cle wasting in rats [62–65], relatively little work has been
done on the MS-based identification of pathological disease
markers in animal models of neuromuscular diseases [112].
One exception is the X-linked muscular dystrophy [113], the
most frequently inherited childhood disease of skeletal
muscles [114], which has been chosen in this review as an
illustrative example of the analytical power of modern prote-
omics [41, 58–61]. The reason for the extensive application of
animal model proteomics in the case of DMD is probably the
long-standing establishment of a variety of animal models
mimicking this progressive disorder, as outlined above [7, 16,
83–86]. The analysis of different groups of dystrophic mus-
cles of varying age and pathological severity from the mdx
mouse has identified several new disease markers, which
have previously been missed by traditional biochemical
approaches. It appears that the primary deficiency in the
membrane cytoskeletal protein dystrophin causes a severe
perturbation of the muscle proteome expression pattern
including elements involved in nucleotide metabolism [58],
cytosolic ion homeostasis [61], Ca21-cycling through the sar-
coplasmic reticulum (SR) [60], and the stress response via
small heat shock proteins [41]. These proteomic findings can
now be correlated to large data sets from various global gene
expression studies with dystrophin-deficient fibres [115–
121]. Expression profiling suggests that cellular changes in
dystrophin-deficient fibres are associated with altered devel-
opmental programming due to abnormal ion handling [115,
116], a chronic inflammatory response [117, 118], infiltration
of connective tissue [118], an early delay in myofibre devel-
opment [119] and a regeneration-inducing activation of sig-
nalling pathways involved in the proliferation and differ-
entiation of satellite cells [120]. Interestingly, dystrophic
muscle lacking both dystrophin and its autosomal homo-
logue utrophin are characterized by the up-regulation of slow
muscle genes [121], suggesting that these sets of genes may
play a central role in the severely dystrophic phenotype. The
results from both proteomic and transcriptomic profiling of
dystrophin-deficient fibres agree that a large cohort of newly
identified muscle components may represent potential tar-
gets for improved drug therapy. This includes elements of
key metabolic pathways, ion homeostasis, stem cell activa-
tion, stress response and inflammation.
Figure 2 gives an overview of the findings from a recent
DIGE analysis of the severely dystrophic diaphragm from
mdx mice. Out of 2398 detectable 2-D protein spots, 35 pro-
teins showed a drastic differential expression pattern, with
21 proteins being decreased, including Fbxo11-protein, ade-
nylate kinase, haemoglobin and dihydrolipoamide dehy-
drogenase, and 14 proteins being increased, including alde-
hyde reductase, desmin, vimentin, stress proteins and myo-
sin heavy chain isoforms [41]. This agrees with the idea that
the lack of the dystrophin isoform Dp427 results in a desta-
bilized membrane cytoskeleton and an increased frequency
of microrupturing of the plasma membrane [122–124]. The
expression pattern of key metabolic marker proteins involved
in nucleotide metabolism, oxygen transportation, glycolysis,
the citric acid cycle, fatty acid oxidation, aldehyde metabo-
lism, the formation of acetyl-coenzyme, acid–base balance,
ion homeostasis and the remethylation pathway are dis-
turbed in the mdx animal model of Duchenne muscular
dystrophy. The loss of metabolic regulators and compensa-
tory up-regulation of key enzymes appears to be the patho-
biochemical consequence of the interruption between the
dystrophin-associated actin membrane cytoskeleton and the
extracellular matrix (ECM) component laminin [122]. The
up-regulation of the intermediate filament proteins vimentin
and desmin in Dp427-deficient fibres is possibly a natural
repair mechanism occurring in dystrophic fibres [41]. By
substituting for the loss of dystrophin, the load-bearing
function of the muscle cytoskeleton may be partially rescued
by the increase in vimentin and desmin. The drastic reduc-
tion of the enzyme adenylate kinase (AK) in both the mildly
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Figure 2. Proteomic profiling of the severely dystrophic mdx diaphragm using DIGE analysis. Shown is the 2-D gel electrophoretic
separation of normal Cy3-labelled (A) and dystrophic Cy5-labelled (B) muscle preparations. DIGE analysis was carried out as previously
described in detail [41]. The pH-values of the first dimension gel system and molecular mass standards (in kDa) of the second dimension
are indicated on the top and on the left of the panels, respectively. Panels (C) and (D) show an expanded view of 2-D gels of normal andmdx
diaphragm, respectively. The position of the 2-D spots representing AK and the stress protein cvHSP are marked by circles. Changes in the
abundance of these two protein in dystrophin-deficient fibres is illustrated in the diagrams of panels (E) to (H), demonstrating the drastic
decrease of AK and concomitant increase of cvHSP in mdx fibres.
dystrophic mdx limb musculature [58, 59] and the severely
dystrophic mdx diaphragm [41, 61], indicates a major meta-
bolic defect in the nucleotide pathway.
The generally perturbed protein expression pattern in
dystrophin-deficient fibres was found to be especially drastic
with respect to a muscle-specific member of the small heat
shock protein family [41], named cvHSP [125]. As can be
seen in the enlargements of the Cy3- and Cy5-labelled 2-D
gels of normal versus dystrophic preparations, the spots
representing AK and cvHSP exhibit the opposite fate during
muscle degeneration (Figs. 2A–D). The comparative graphic
representation of the 2-D spots under investigation shows
the drastic reduction in AK and concomitant increase in the
expression of cvHSP in mdx diaphragm fibres (Figs. 2E–H).
2-D immunoblotting has confirmed these proteomic find-
ings. Figure 3 shows the immunodetection of the stress pro-
tein cvHSP. In contrast to the unaltered abundance of the
heat shock protein HSP60 and a decrease in the cystosolic
Ca21-binding protein regucalcin in mdx fibres, the expres-
sion of cvHSP is drastically increased in both young and old
dystrophin-deficient fibres [41, 61]. The sub-family of small
heat shock proteins is mostly involved in the stabilization of
cytoskeletal protein folding and transportation which
strongly indicates that the increase in cvHSP is an autopro-
tective mechanism of dystrophic fibres in an attempt to res-
cue their cellular integrity by modulating and repairing the
cytoskeletal network [126, 127]. The above outlined findings
from animal model proteomics suggest that modulating the
stress response might be beneficial to damaged muscle
Figure 3. 2-D immunoblot analysis of the severely dystrophic
mdx diaphragm. Shown are 2-D immunoblots of normal (lane 1)
and dystrophic mdx (lane 2) preparations that have been labelled
with antibodies to the heat shock protein HSP60, the small mus-
cle-specific stress protein cvHSP and the cytosolic Ca21-binding
protein regucalcin (RGN). Regucalcin is also named senescence
marker protein SMP-30. The age of the muscles used in this
analysis is marked at the left side of the blots (wk, weeks; m,
months). 2-D immunoblotting was performed by standard meth-
ods as recently described by our laboratory [41].
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fibres. Interestingly, heat shock treatment enhances the sur-
vival rate of transplanted myoblasts [128], demonstrating the
important role of the stress response in muscle regeneration
[129].
The calcium hypothesis of muscular dystrophy assumes
that a combination of membrane rupturing, faulty repair
mechanisms, abnormal ion fluxes and an impaired regula-
tion of the excitation–contraction–relaxation cycle renders
muscle fibres more susceptible to necrosis [130]. It is well
established that Ca21-cycling through the cytosol, sarco-
lemma, SR and mitochondria is disturbed in dystrophic
fibres. The lack of dystrophin and resulting loss in the dys-
trophin-associated glycoprotein complex appears to damage
the integrity of the skeletal muscle surface to such an extent
that increased rupturing of the sarcolemma initiates a natu-
ral membrane resealing process [131]. However, the intro-
duction of sarcolemmal Ca21-leak channels triggers a drastic
elevation of cytosolic Ca21-levels [132], which in turn causes
proteolysis and thereby muscle degeneration [131]. A com-
plicating factor is the decreased Ca21-buffering capacity of
the SR due to low levels of the Ca21-binding proteins calse-
questrin (CSQ) [60], CSQ-like proteins [95] and sarcalume-
nin (SAR) [96], and impaired cystosolic Ca21-binding due to a
reduction in regucalcin [41, 61]. Since the cystosolic Ca21-
concentration is the most important second messenger sys-
tem with respect to many muscle functions including EC
coupling, fibre relaxation, metabolic integration and fibre
differentiation, abnormal Ca21-handling has severe patho-
logical consequences [133]. The diagram in Fig. 4 outlines
the current working hypothesis of the molecular pathogen-
Figure 4. Overview of abnormal Ca21-handling in dystrophin-deficient fibres as revealed by proteomic profiling of the mdx mouse model
of DMD. Shown is a diagrammatic presentation of the main membrane systems involved in the regulation of the excitation–contraction–
relaxation cycle. The contractile status of a skeletal muscle fibre is dictated by the cytosolic Ca21-concentration, which regulates both
contractile activity via the troponin C system (TnC) and the relaxation-inducing pump activity of the sarcoplasmic reticulum Ca21-ATPase
(SERCA). Proteomic profiling of the mdx model has revealed that a reduced expression of the cytosolic Ca21-binding protein regucalcin
(RGN) and the luminal CSQ and SAR of the SR triggers abnormal ion homeostasis in dystrophic fibres. This results in a lower Ca21-capacity
of the luminal SR and the cytosolic ion-binding reservoir. In addition, abnormal EC coupling between the dihydropyridine receptor (DHPR)
and the ryanodine receptor (RyR) Ca21-release channel at the triad junction in the transverse tubules (TT) and the introduction of Ca21-leak
channels into the sarcolemma (SL) following membrane resealing exacerbates abnormal ion handling. Elevated cytosolic Ca21-levels were
shown to trigger an increased rate of proteolytic degradation of muscle proteins thereby rendering fibres more susceptible to necrosis.
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esis of muscular dystrophy based on the proteomic analysis
of Ca21-handling proteins. This included the subproteomic
study of Ca21-binding proteins by ‘Stains All’ labelling [60],
the conventional proteomic profiling of soluble muscle pro-
teins by Coomassie staining [61], and the comparative prote-
omic analysis of normal versus dystrophic fibres by DIGE
screening [41].
Besides necrotic and regenerative muscle fibres, pro-
gressive muscle wasting in X-linked muscular dystrophy is
also associated with an increase of endomysial fat and con-
nective tissue, as well as infiltration by immune cells [81,
114]. The analytical problem of dealing with nonmuscle cells
can be addressed by careful prefractionation of tissue speci-
mens or using the sensitive proteomic profiling technique
itself for a differential analysis. High-resolution 2-DE in
combination with MS identification tools is such a sensitive
analytical approach that it can differentiate effects in hetero-
geneous cell mixtures. On the other hand, a prior manipula-
tion of tissues, such as the extraction of different cell types
from muscles by cell biological techniques, may introduce
artefacts or more importantly decrease the amounts of avail-
able tissue for a proper proteomics analysis. Thus, despite
the fact that tissue heterogeneity increases the complexity of
a proteomic profiling exercise, a biochemical strategy using
total muscle extracts should be successful for identifying
new disease markers that play a central role in neuromus-
cular diseases. The screening of cell-specific biomarkers
indicative of motor neurons, capillaries, connective tissue,
fatty tissue and immune cells can be employed to judge
drastic changes in these nonmuscle fibre cell types existing
in muscles. In analogy to the identified changes in immune
response and connective tissue composition as revealed by
transcriptomic studies [117, 118], sensitive proteomic tech-
niques such as DIGE analysis should be able to identify
markers of fibrosis, inflammation and fatty tissue accumu-
lation during muscle fibre degeneration.
4.4 Proteomic profiling of muscle aging
The comparative proteomic profiling of young versus old rat
skeletal muscle by Piec et al. [65] revealed a differential
expression pattern for various soluble proteins, such as ele-
ments of the contractile apparatus, the cytoskeleton, reg-
ulatory proteins, cytosolic and mitochondrial proteins
involved in metabolism, and chaperones. The previous
observation from biochemical studies of senescent muscles,
that aging has a profound effect on many essential cellular
processes [134], was confirmed by animal model proteomics.
Sarcopenia appears to be associated with changes in the
expression levels of key muscle proteins including actin,
myosin light chains, troponin, desmin, tubulin, gelsolin,
triose-phosphate isomerase, enolase, glycerol–phosphate
dehydrogenase creatine kinase, isocitrate dehydrogenase,
cytochrome-c oxidase, aldehyde dehydrogenase, glutathione
transferase, glyoxalase, RNA-editing proteins and various
chaperones [65]. These severe alterations may play a central
role in the dysfunctions in aged muscle force generation and
speed of contraction. It is believed that a variety of biochem-
ical and cell biological factors play a role in the functional
decline of aging muscles and it is difficult to determine
whether a molecular pathological hierarchy and/or inter-
dependence exists between the variousmetabolic insults or if
one overriding pathological change triggers a cascade of
pathophysiological down-stream responses [135]. Since the
biological changes observed following denervation of a
motor unit are similar to the natural muscle aging process,
sarcopenia might be at least partially due to abnormal inner-
vation. This would be in agreement with the generally
observed loss of active motor units and a shift to a slower
twitching phenotype in aged muscles [136, 137]. Besides
dennervation, other factors involved in the loss of muscle
mass and strength is the decreased protein synthesis of con-
tractile muscle proteins, a progressive deterioration in
energy intake, mitochondrial decline leading to an impaired
energy supply to muscle cells, a disturbed equilibrium of
growth factors and hormones essential for the maintenance
of basic muscle function, modified gas and metabolite
exchange rates due to decreased capillarization, extensive
oxidative stress, increased triggering of apoptotic pathways,
impaired ion handling leading to disturbed ion fluxes,
abnormal metabolic regulation and a decreased availability
of satellite cells [138–145]. Future DIGE-based analyses of
aging muscle will hopefully identify a new range of bio-
markers associated with sarcopenia. Once new aging-related
protein factors have been shown to play a critical role in
senescent muscle degeneration, novel therapeutic routes can
be designed to counter-act one of the most devastating
pathologies of old age.
5 Impact of animal studies on clinical
proteomics
Although the identification of the primary genetic abnorm-
ality in an inherited disease or the determination of genetic
factors that may predispose an organism to a certain pathol-
ogy are in themselves remarkable scientific achievements,
this biomedical knowledge does not necessarily translate into
the quick development of a cure for these disorders. The hu-
man body consists of billions of cells forming a highly com-
plex and metabolically integrated system that reacts to a
genetic or environmental insult through the utilization of
compensatory mechanisms and activation of alternative
pathways. It is very difficult to predict at what point in time
during a pathophysiological process the natural defence and
repair mechanisms are exhausted and severe cellular dam-
age starts to occur. Metabolic changes are often complex and
a hierarchy may exist in degenerative pathways. These bio-
logical alterations are reflected in the constant change of the
proteome during a patient’s lifetime. Thus, in contrast to the
limited information one can deduce from genomic data with
respect to disease progression, the analysis of changes in the
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protein complement of an affected tissue or organ over time
may give important clues on secondary and tertiary altera-
tions. However, most human diseases show a whole array of
symptoms with interindividual differences in severity and
progression, making it often difficult to identify disorder-
specific biomarkers. This gives animal model research an
important place in biomedical studies. To outline the poten-
tial impact of animal proteomics studies on subsequent
clinical proteomic profiling exercises, the findings from the
DIGE screening of the mdx mouse model of DMD are taken
as an example [41] and discussed with respect to their bio-
medical importance.
In the case of Duchenne muscular dystrophy, it has been
known for almost two decades that point mutations or
genetic rearrangements in the dystrophin gene, located in
the chromosomal Xp21 region, are the underlying reason for
progressive muscle wasting [146]. The enormous size and
complexity of the dystrophin gene is possibly a major factor
for the high frequency of this neuromuscular disease in
young boys. Extensive biochemical studies on the function of
dystrophin and its associated surface glycoproteins indicate
that the loss of the linkage between the actin membrane
cytoskeleton and the ECM is the initial cellular damage in
dystrophin-deficient fibres [122]. A drastic reduction in the
sarcolemma-spanning dystrophin–DG complex severely
impairs the integrity of the muscle periphery [123]. It is not
known how many secondary steps lead from this weakening
of the plasma membrane to triggering the end-stage dys-
trophic phenotype with necrosis, fibrosis and fatty tissue
infiltration [147]. Although abnormal Ca21-handling has
clearly been identified as a major factor in rendering muscle
fibres more susceptible to proteolytic degradation, it is not
well understood how altered ion fluxes trigger complex
changes in metabolic regulation and signal transduction
processes. On the level of the muscle fibre, necrosis is clearly
the key mechanism which causes a decline in muscle mass
and strength in patients suffering from X-linked muscular
dystrophy. However, several years of a symptom-free stage is
present in very young patients, suggesting that compensa-
tory mechanisms based on the up-regulation of dystrophin
homologues and/or the rescue by satellite cell proliferation
exists. Once the body starts to loose sufficient numbers of
muscle precursor cells, dystrophic changes will inevitably
lead to muscle wasting. The missing link between the initial
cellular defect via the loss of the dystrophin–glycoprotein
complex and the final disintegration of muscle cells is the
molecular pathogenesis bridging these two events [123].
As outlined in the flow chart of Fig. 5, the recent DIGE
analysis of the severely dystrophic diaphragm from the mdx
mouse model of DMD has revealed a large number of bio-
logical processes being affected in dystrophin-deficient
fibres. Muscle proteins of increased abundance can be
grouped as components involved in chaperone function
(cardiovascular heat shock protein; chaperonin), aldehyde
metabolism (aldehyde reductase), intermediate filament for-
mation (desmin; vimentin), muscle contraction (myosin
Figure 5. Flow chart of biomarker identification for muscular
dystrophy. Shown is a diagram of the dystrophin–glycoprotein
complex and its role in dystrophinopathies. Both, in DMD and the
dystrophic mdx mouse model, the Dp427 isoform of the mem-
brane cytoskeletal protein dystrophin is absent, triggering a
reduction in the dystrophin-associated glycoprotein complex. In
normal muscle, the a/b-DG subcomplex provides a trans-sarco-
lemmal linkage between the ECM element laminin (LAM) and the
actin membrane cytoskeleton. Other proteins that exist in close
proximity to dystrophin are DB, SYN, SS and the SG. The prote-
omic profiling of the mdx mouse model of X-linked muscular
dystrophy has resulted in the establishment of a new cohort of
potential biomarkers of DMD. The biological processes, in which
proteins with a disturbed expression pattern are involved in, are
listed in the diagram.
heavy chains), glycolysis (glyceraldehyde-3-phosphate dehy-
drogenase), fatty acid oxidation (electron transferring flavo-
protein) and nucleotide metabolism (Atp5b protein). In con-
trast, diaphragm proteins of decreased abundance are
involved in protein ubiquination (Fbxo11 protein), nucleo-
tide metabolism (adenylate kinase; creatine kinase), oxygen
transport (b-haemoglobin; a-globin), mitochondrial
enzymes associated with the formation of acetyl-coenzyme A
(dihydrolipoamide dehydrogenase), muscle contraction
(myosin light chain; troponin; actin), glycolysis (aldolase),
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aldehyde metabolism (aldehyde dehydrogenase), the
remethylation pathway of homocysteine homeostasis (beta-
ine-homocysteine methyltransferase), cytosolic calcium
homeostasis (regucalcin), the polyol pathway of glucose me-
tabolism (sorbitol dehydrogenase), the citric acid cycle (iso-
citrate dehydrogenase), the regulation of acid-base balance
(carbonic anhydrase), and transcriptional control (jumonji-
domain containing Jmjd1a protein) [41]. The disease-specific
character of this new cohort of potential biomarkers of dys-
trophinopathy can now be tested by immunoblotting,
immunofluorescence microscopy and comparative prote-
omics of human biopsy specimens, showing the usefulness
of animal model proteomics as an initial enabling tool for
clinical proteomics.
6 Conclusions
Based on the enormous impact proteomics had on biomedi-
cal studies over the last few years [148–150], it can be expec-
ted that the proteomic profiling of animal disease models
will have a considerable influence on the improved design of
diagnostic procedures, the evaluation of experimental treat-
ment strategies such as stem cell and gene therapy, and the
detailed biochemical phenotyping of new disease model sys-
tems. Since end-stage pathologies may involve similar
degenerative pathways, it is important to distinguish be-
tween common indicators of general cellular destruction and
subsets of more precise markers of a particular disease. Such
knowledge can then be used to decisively improve the iden-
tification of new therapeutic targets. Since most complex
human diseases are multifactorial and affect more than one
tissue or organ, in the future multiple animal models
mimicking particular aspects of a human pathology will be
employed in order to properly study all aspects of a particular
etiology. Thus, the genetic engineering of animal models will
play an essential role in the study of the molecular and cel-
lular changes caused by a genetic or environmental insult.
Besides genetic rodent models, also nonmammalian sys-
tems such as zebrafish and nematodes will probably become
more important due to the ease of genetic manipulation and
analysis of physiological changes. In this respect, the ulti-
mate goal of animal model proteomics is to facilitate the
establishment of improved disease models and the identifi-
cation of novel highly disease-specific biomarkers which can
be employed for the predictive evaluation of new treatment
strategies for human diseases.
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